Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

Company Overview

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder. The company also develops plasma-derived therapies and vaccines through its research and manufacturing operations.

Founded in Osaka in 1781 by Chobei Takeda I, Takeda has evolved from a traditional Japanese medicine business into a multinational biopharmaceutical company. Its medicines and services are available in Japan, the United States, Europe and other markets worldwide. Takeda’s global expansion was significantly strengthened by its acquisition of Shire plc, completed in 2019. Christophe Weber has served as the company’s president and chief executive officer since 2014.

Key Stats

• Today's Range: $19.56 to $19.71
• 50-Day Range: $17.39 to $19.70
• 52-Week Range: $12.99 to $19.89
• Volume: 2.83 million shs
• Average Volume: 2.72 million shs
• Market Capitalization: $63.11 billion
• P/E Ratio: 11.58
• Dividend Yield: 2.44%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Takeda Pharmaceutical Stock Analysis - MarketRank™

Takeda Pharmaceutical scored higher than 44% of companies evaluated by MarketBeat, and ranked 712th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Takeda Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Takeda Pharmaceutical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -10.26%

Earnings Growth

Earnings for Takeda Pharmaceutical are expected to decrease by -10.26% in the coming year, from $1.56 to $1.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Takeda Pharmaceutical is 11.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Takeda Pharmaceutical is 11.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 192.53.

Price to Book Value per Share Ratio

Takeda Pharmaceutical has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.09% of the float of Takeda Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Takeda Pharmaceutical has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Takeda Pharmaceutical has recently decreased by 30.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Takeda Pharmaceutical pays a meaningful dividend of 2.47%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Takeda Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Takeda Pharmaceutical is 141.18%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 34.29% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.39

News Sentiment

Takeda Pharmaceutical has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Takeda Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,981,175.00 in company stock.

Percentage Held by Insiders

0.04% of the stock of Takeda Pharmaceutical is held by insiders.

Percentage Held by Institutions

9.17% of the stock of Takeda Pharmaceutical is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:TAK
• CIK: 1395064
• Web: www.takeda.com
• Phone: +81332782111
• Fax: 813-3278-2268
• Employees: 47,000
• Year Founded: 1781

Profitability

• EPS (Trailing Twelve Months): $0.34
• Trailing P/E Ratio: 11.58
• Forward P/E Ratio: 12.63
• P/E Growth: N/A
• Net Income: -$1.01 billion
• Net Margins: 3.80%
• Pretax Margin: -3.16%
• Return on Equity: 10.95%
• Return on Assets: 5.34%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 1.14
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $28.32 billion
• Price / Sales: 2.23
• Cash Flow: $3.14 per share
• Price / Cash Flow: 6.27
• Book Value: $15.41 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 3,204,280,000
• Free Float: 3,203,001,000
• Market Cap: $63.11 billion
• Optionable: Optionable
• Beta: -0.07